Nutritional and metabolic advances in inflammatory bowel disease

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 1, Issue 5, 1998, Pages 387-390

  Burke, Anne ^a   Lichtenstein, Gary R ^a   Rombeau, John L ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID DERIVATIVE;

ANIMAL; DIET; ENTERITIS; HUMAN; METABOLIC BONE DISEASE; METABOLISM; NUTRITIONAL DISORDER; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; BONE DISEASES, METABOLIC; BUTYRATES; DIET; HUMANS; INFLAMMATORY BOWEL DISEASES; NUTRITION DISORDERS;

EID: 0032152011     PISSN: 13631950     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075197-199809000-00002     Document Type: Article

References (23)

1. Burke A, Lichtenstein GR, Rombeau JL. Nutrition and ulcerative colitis. In: Ulcerative colitis. Gibson PR, editor. London: WB Saunders; 1997. pp. 153-174. A comprehensive review of the role of nutrition in ulcerative colitis
2. Reif S, Klein I, Lubin F, Farbstein M, Hallak A, Gilat T. Pre-illness dietary factors in inflammatory bowel disease. Gut 1997; 40:754-760.
3. Messori A, Trallori G, D'albasio G, Milla M, Vannozzi G, Pacini F. Defined-formula diets versus steroids in the treatment of active Crohn's disease. Scand J Gastroenterol 1996; 31:267-272.
4. Azcue M, Rashid M, Griffiths A, Pencharz PB. Energy expenditure and body composition in children with Crohn's disease: effect of enteral nutrition and treatment with prednisolone. Gut 1997; 41:203-208.
5. Geerling B, Badart-Smook A, Stockbrugger RW, Brummer R. Comprehensive nutritional status in patients with long-standing Crohn disease currently in remission. Am J Clin Nutr 1998; 67:919-926.
6. Jeejeebhoy KN. The many faces of malnutrition in Crohn disease. Am J Clin Nutr 1998; 67:819.
7. Geerling B, Van Deursen C, Stockbrugger RW, Brummer R. Improved antioxidant status after supplementation with n-3 fatty acids and/or antioxidants in addition to a regular diet in patients with Crohn's disease in a double blind placebo controlled study [abstract]. Gastroenterology 1998; 114:A983.
8. Geerling B, Van Houwelilngen AC, Stockbrugger RW, Brummer R. The effect of antioxidants/n-3 fatty acids supplementation on the plasma phospholipid fatty acid pattern and disease activity in patients with Crohn's disease in a double blind placebo controlled study [abstract]. Gastroenterology 1998; 114:A984.
9. French MA, Parrott AM, Kielo ES, Rajotte RV, Wang LCH, Thomson ABR, Clandinin MT. Polyunsaturated fat in the diet may improve intestinal function in patients with Crohn's disease. Biochim Biophys Acta 1997; 1360:262-270.
10. Siguel EN, Lerman RH. Prevalence of essential fatty acid deficiency in patients with chronic gastrointestinal disorders. Metabolism 1996; 45:12-23.
11. Schoon EJ, Geerling B, Schurgers L, Vermeer C, Stockbrugger RW, Brummer R. Bone formation is suppressed and bone resorption is normal in long-standing quiescent Crohn's disease [abstract]. Gastroenterology 1998; 114:A1080.
12. Schulte C, Dignass AU, Ortmans S, Mann K, Goebell H. Bone mineral density in IBD patients: a prospective longitudinal study [abstract]. Gastroenterology 1998; 114:A1081.
13. Silverberg MS, Mikolainis S, Steinhart AH. Low bone mineral density (BMD) in Crohn's disease (CD) occurs independent of corticosteroid use [abstract]. Gastroenterology 1998; 114:A1086.
14. Gokhale R, Favus MJ, Karrison T, Sutton MM, Rich B, Kirschner BS. Bone mineral density assessment in children with inflammatory bowel disease. Gastroenterology 1998; 114:902-911.
15. Koniaris SG, Fisher SE, Rubin CT, Chawla A. Experimental colitis impairs linear bone growth independent of nutritional factors. J Pediatr Gastroenterol Nutr 1997; 25:137-141.
16. Moore JWE, Millard S, Babidge W, Rowland R, Roediger WEW. Hydrogen sulphide produces diminished fatty acid oxidation and in the rat colon in vivo: implications for ulcerative colitis. ANZ J Surg 1997; 67:245-249. Further exploration of the interaction between hydrogen sulphide and butyrate oxidation by colonocytes. Butyrate oxidation was impaired as expected but was not accompanied by histological changes. The interaction is not yet fully elucidated.
17. Richter F, Scheppach W. Innovations in topical therapy. In: Ulcerative Colitis. Gibson PR, editor. London: WB Saunders; 1997. pp. 97-109.
18. Kim Y. Short-chain fatty acids in ulcerative colitis. Nutr Rev 1998; 56:17-24.
19. Cummings JH. Short-chain fatty acid enemas in the treatment of distal ulcerative colitis. Eur J Gastroenterol Hepatol 1997; 9:149-153.
20. Scheppach W, Muller JG, Boxberger F, Dusel G, Richter F, Bartram HP, et al. Histological changes in the colonic mucosa following irrigation with short-chain fatty acids. Eur J Gastroenterol Hepatol 1997; 9:163-168. An important human study. Patients suffering with ulcerative colitis when administered short-chain fatty acids (SCFA) demonstrated decreased hyperproliferation of the colonic mucosa but not histologic improvement.
21. Kanauchi O, Iwanaga T, Saiki T, Nakamura T, Agata K, Toyonaga A, Tanikawa K. Efficacy, safety and tolerance of germinated barley foodstuff (GBF) feeding in humans [abstract]. Gastroenterology 1998; 114:A895.
22. Kanauchi O, Mitsuyama K, Saiki T, Tanikawa K, Iwanaga T. Germinated barley foodstuff induces butyrate production and enhances mucosal barrier function in the colon of experimental colitis [abstract]. Gastroenterology 1998; 114:A887.
23. Loftus EV, Tremaine JR, William J, Nelson RA, Shoemaker JD, Sandborn WJ, et al. Dexpanthenol enemas in ulcerative colitis: a pilot study. Mayo Clin Proc 1997; 72:616-620. A novel approach to the problem of impaired utilisation of butyreted by colonocytes. Unfortunately administration of large doses of panthotheric acid failed to overcome the putative metabolic defects in fuel utilisation in colonocytes of ulcerative colitis patients.